Myriam Curet Sells 408 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) EVP Myriam Curet sold 408 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $589.75, for a total transaction of $240,618.00. Following the sale, the executive vice president now owns 353 shares of the company’s stock, valued at approximately $208,181.75. This represents a 53.61 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Intuitive Surgical Price Performance

ISRG opened at $591.65 on Wednesday. The stock has a market capitalization of $210.73 billion, a PE ratio of 92.30, a P/E/G ratio of 5.67 and a beta of 1.39. The firm’s fifty day moving average price is $555.91 and its 200 day moving average price is $515.92. Intuitive Surgical, Inc. has a 12-month low of $364.17 and a 12-month high of $616.00.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Raymond James boosted their price objective on shares of Intuitive Surgical from $560.00 to $688.00 and gave the stock an “outperform” rating in a research note on Friday, January 24th. JPMorgan Chase & Co. boosted their price objective on shares of Intuitive Surgical from $575.00 to $675.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. The Goldman Sachs Group set a $604.00 price objective on shares of Intuitive Surgical in a research note on Friday, October 18th. Mizuho boosted their price objective on shares of Intuitive Surgical from $440.00 to $500.00 in a research note on Thursday, October 17th. Finally, Jefferies Financial Group boosted their price objective on shares of Intuitive Surgical from $475.00 to $575.00 in a research note on Monday, January 27th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $613.10.

Institutional Trading of Intuitive Surgical

Several institutional investors have recently added to or reduced their stakes in the stock. Signature Estate & Investment Advisors LLC acquired a new stake in Intuitive Surgical in the fourth quarter valued at $343,000. First American Trust FSB raised its holdings in Intuitive Surgical by 65.0% in the fourth quarter. First American Trust FSB now owns 858 shares of the medical equipment provider’s stock valued at $448,000 after acquiring an additional 338 shares in the last quarter. Zions Bancorporation N.A. raised its holdings in Intuitive Surgical by 7.0% in the fourth quarter. Zions Bancorporation N.A. now owns 12,391 shares of the medical equipment provider’s stock valued at $6,468,000 after acquiring an additional 814 shares in the last quarter. TIAA Trust National Association raised its holdings in Intuitive Surgical by 9.9% in the fourth quarter. TIAA Trust National Association now owns 2,763 shares of the medical equipment provider’s stock valued at $1,442,000 after acquiring an additional 248 shares in the last quarter. Finally, FineMark National Bank & Trust raised its holdings in Intuitive Surgical by 1.5% in the fourth quarter. FineMark National Bank & Trust now owns 21,378 shares of the medical equipment provider’s stock valued at $11,158,000 after acquiring an additional 316 shares in the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.